Publications by authors named "A Madejon"
Background: Vaccine hesitancy and lack of access remain major issues in disseminating COVID-19 vaccination to liver patients globally. Factors predicting poor response to vaccination and risk of breakthrough infection are important data to target booster vaccine programs. The primary aim of the current study was to measure humoral responses to 2 doses of COVID-19 vaccine.
View Article and Find Full Text PDFArticle Synopsis
- Mongolia has a high rate of viral hepatitis infections (B, C, D), prompting a community program aimed at increasing awareness and screening among Mongolians living in Spain.
- The program included educational activities, epidemiological questionnaires, and rapid hepatitis testing, with 79% attendance from invited participants, predominantly women with an average age of 42.
- Results revealed several positive hepatitis cases; the educational component significantly boosted participants' knowledge levels, and the initiative successfully linked 22 individuals to care, half of whom were previously unaware of their infection status.
Introduction: Cellular epigenetic modifications occur in the course of viral infections. We previously documented that hepatitis C virus (HCV) infection of human hepatoma Huh-7.5 cells results in a core protein-mediated decrease of Aurora kinase B (AURKB) activity and phosphorylation of Serine 10 in histone H3 (H3Ser10ph) levels, with an affectation of inflammatory pathways.
View Article and Find Full Text PDFBackground And Aims: HIV-positive patients on tenofovir hydroxyl fumarate (TDF)/emtricitabine have a lower risk of COVID-19 and hospitalization than those given other treatments. Our aim was to analyze the severity of COVID-19 in patients with chronic hepatitis B (CHB) on TDF or entecavir (ETV).
Methods: Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19.
Article Synopsis
- The study examines fluctuations in HDV-RNA levels in patients with chronic hepatitis delta (CHD) to understand how it relates to other hepatitis B markers.
- Approximately 25% of the patients experienced a significant decrease in HDV-RNA over an average follow-up period of 5.6 years, with 20% achieving undetectable levels.
- The research suggests that declines in HDV-RNA are linked to improvements in liver enzyme levels, hinting at potential new treatment strategies for CHD.